TEL AVIV, Israel, Jan. 5, 2021 /PRNewswire/ -- Stero Biotechs, an Israel-based, clinical-stage company focused on Cannabidiol (CBD) formulation research and development, is proud to supply and support a clinical trial, covered by its' IP for Cannabidiol Treatment of Severe and Critical COVID-19 Pulmonary Infection, at Rabin Medical Center, (RMC), the leading hospital of Clalit HMO, in the global efforts of fighting the COVID-19 virus.
The investigator initiated clinical study, which runs in cooperation of Stero and Mor Research applications, the TTO arm of Clalit, commenced immediate with the strike of the 'second wave' and rise in patient amount in Israel, due to the COVID-19 pandemic. The clinical trial already received Helsinki Committee approval and is planned for 20 patient treatment as a Proof of Concept ('POC'), using Stero's CBD-based treatment, conducted by Dr. Ilya Kagan from the intensive care department with the support of Dr. Moshe Yeshurun, Director of the Bone Marrow Transplantation Unit, at Rabin Medical Center, Israel.
The study aims to benefit and help COVID-19 patients in severe states with respiratory failure from acute respiratory distress syndrome (ARDS). The treatment cycle will be for 14-28 days with a subsequent follow-up period of the same length. Pending the success of this POC, Stero plans to expand and scale phase 2a multi-center study, with an additional 40 patients, under FDA clinical trial guidelines and regulations.
David Bassa, Founder & CEO of Stero Biotechs said: "After the amazing discovery at Oxford of dexamethasone (a steroid treatment) it is our top priority to contribute to the effort of saving lives using our CBD-based treatment for enhancing the therapeutic effect of a steroid treatment, as covered by our IP, in order to reduce death caused by 'Cytokine Storm'."
About Stero Biotechs, Ltd.
STERO Biotechs Ltd., founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel Cannabidiol (CBD) based treatment solutions that will potentially benefit millions by: 1) Enhancing the therapeutic effect of steroid treatments .2) Lowering the dosage needed in steroid treatments, thus lowering the treatment's horrific side effects. 3) Allowing refractory patients to begin responding to the steroid treatments needed. All by using Stero's CBD-based treatment. Stero's patent was issued on the U.S. and covers over 130 indications by name, CBD from any source (botanical or synthetic), any dosage, in any combination & any delivery system. Stero has 2 ongoing phase 2a clinical trials in Crohn's Disease & in Urticaria (Hives) in Israeli hospitals and is planning to commence more clinical trials in 2020-2021 on various indications.
Stero has established a strong partnership with one of its shareholders- MOR Research Applications, the TTO of CLALIT HEALTH SERVICES.
CLALIT is the largest HMO in ISRAEL, with:
- Over 4.5M members
- 14 full-scale hospitals
- Over 2000 community clinics
- Over 9000 physicians.
The partnership with MOR allows deep support to Stero's clinical trials.
For any inquiries, please feel free to contact us at [email protected]
SOURCE Stero Biotechs